Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, cosmetic practices such as non-ablative lasers, autologous fat injections, and oral isotretinoin may help alleviate certain symptoms of frontal fibrosing alopecia, while treatments like deep chemical peels and ablative laser therapies are contraindicated due to potential scarring risks.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This report documented a successful and sustained hair restoration surgery using follicular unit transplantation for temporal triangular alopecia, lasting over six years.

This abstract introduces the concept of follicular units (FUs) in the human scalp but presents no new research findings.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This review discusses fibrosing frontal alopecia, including its causes, mechanisms, and treatments, and emphasizes the need for further research to improve understanding and treatments; it reports no new clinical results.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This review provides a synopsis of 53 cases of temporal triangular alopecia, noting its frequent detection in early childhood and potential association with congenital diseases, but it reports no new clinical findings.

Frontal fibrosing alopecia may be caused by an autoimmune reaction and hormonal imbalance.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This study reported six pediatric cases of temporal triangular alopecia and highlighted the use of trichoscopy to distinguish it by detecting a distinctive carpet of vellus hair, helping to differentiate TTA from other hair loss conditions.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

This paper presents consensus guidelines for standardized diagnostic criteria and assessment methods for frontal fibrosing alopecia to improve clinical research and data collection globally.

This case report describes a unique presentation of frontal fibrosing alopecia characterized by a hair loss pattern that resembles the Greek letter upsilon, supported by trichoscopic and histological findings.

This abstract does not contain research results or findings.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This review article highlights recent progress and challenges in stem cell transplantation for regenerative medicine, emphasizing its potential in tissue repair for conditions like bone and cartilage injuries, neurological disorders, and blood diseases, while stressing the importance of overcoming current obstacles for future advancements.

This study found that optimizing proteomic genotyping conditions from single human hair samples significantly improves the detection of genetically variant peptides, enhancing human identification with high precision across different biogeographic backgrounds.

This study found that mimosine dipeptide enantiomers inhibit melanogenesis and cyclooxygenase enzymes in B16F10 melanoma cells, suggesting potential for treating skin hyperpigmentation and inflammation.

This ex vivo study reported that melatonin significantly improved certain aging biomarkers in aged human skin, including reduced mTORC1 activity, increased fibrillin-1, and enhanced collagen and elastic fiber organization, though other key biomarkers remained unchanged.

This study found that preconditioning adipose-derived stem cells with HB-EGF enhanced their ability to promote hair growth in vivo by increasing their motility, paracrine effects, and survival.

This study found that topically applied melatonin exerts significant anti-aging effects on human scalp skin ex vivo, including increased SIRT1 expression and reduced mTORC1 pathway activity.

This paper discusses the importance of early diagnosis and treatment of polycystic ovarian syndrome to potentially reduce long-term complications like diabetes, hypertension, and heart disease, but reports no new clinical outcomes.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.